President Trump's initiatives like TrumpRx, MFN pricing, and pharma deals aimed to lower drug costs amid widespread public concern (60% worried per KFF). Some discounts emerged for cash-paying patients on fertility and GLP-1 drugs, but critics note opacity, limited scope, and ongoing price hikes (1,000 brands up in Jan 2026). Medicare negotiations deliver major savings ($20B+ annually), continuing Biden-era program, while branded discounts often compete with cheaper generics.
As the founder and primary investigative voice at Kodawire, Elijah Tobs brings over 15 years of experience in dissecting complex geopolitical and financial systems. His work is centered on the ethical governance of emerging technologies, the shifting architectures of global finance, and the future of pedagogy in a digital-first world. A staunch advocate for high-fidelity journalism, he established Kodawire to be a sanctuary for deep-dive intelligence. Moving away from the ephemeral nature of modern headlines, Kodawire delivers permanent, verified insights that challenge the status quo and empower the global reader.
Americans facing steep prescription costs at the pharmacy. (Credit: cottonbro studio via Pexels)
Americans are fed up. **Sixty percent** of us worry about affording prescriptions, according to a recent KFF poll. Over eighty percent call those prices unreasonable. And get this: we shell out about three times more for the same meds as folks in other countries. Enter Donald Trump, promising to slash those costs with letters to drugmakers, White House deal-making sessions, a "most favored nation" pricing push for Medicaid, the TrumpRx discount site, and faster approvals for biosimilars. Sounds bold, right? But as I dug into this, the picture gets murkier.
My Take: Why Drug Prices Keep Me Up at Night
Look, I've followed health policy for years, and as someone who's grabbed a Sweetgreen salad in DC while scrolling KFF updates on my phone, this hits personal. My neighbor in Virginia just switched jobs and lost her insulin coverage, classic story. I think Trump's flash works for headlines, but real relief? It demands boring stuff like patent reform and global benchmarking. We're talking lives here, not politics. In my view, patients win only if we force transparency, not just photo ops. Why does this matter to you? Because next time you're at the pharmacy, that copay could break the bank.
"60% of U.S. adults say they or a family member have difficulty affording prescription medicines."
That stat, straight from KFF, underscores the crisis. For everyday folks like us, it's not abstract.
The Contrarian View: Trump's Deals Are More Sizzle Than Steak
Now, you might be wondering: isn't any discount a win? Hold on. Critics like Harvard's Aaron Kesselheim call these one-off publicity stunts, opaque, unenforceable, and no fix for the broken system. People disagree here big time. Trump fans cheer the showmanship; skeptics say it distracts from pharma's pricing power. Let's be honest: if prices keep climbing despite the hype, was it all theater? I watched the original video so you don't have to. The creator glossed over how Medicaid already gets deep discounts, making MFN slim pickings for most. Here's the other side: even Mark Cuban admits any patient savings count, but business-as-usual hikes in 2026 tell a different story.
Unpacking TrumpRx: Flashy Discounts, But Check the Fine Print
TrumpRx discounts accessible via GoodRx app for cash-paying patients. (Credit: Adriana Beckova via Pexels)
Launched February 6, TrumpRx targets cash-paying patients with deals via GoodRx coupons. Trump touted one-on-ones with 16-plus pharma execs, including Pfizer's Albert Bourla for 30-plus drugs. Savings up to **85%**, they claim. Pfizer says it's a win for patients, leadership, and their bottom line.
Examples? Colestid drops to $127.91, "50% off", but Cost Plus generics run $17. Cortef (hydrocortisone 5mg) hits $45 versus $91.80 list, still pricier than alternatives. Viracept for HIV? $607.20, and you need combos not on discount. Humira from AbbVie: $950 per dose versus $7,000 list, but biosimilars are just $207.60. Xeljanz for arthritis stays at $1,518 monthly, better than $2,277, but cash unaffordable for many.
Bright spots: EMD Serono's Gonal-F for fertility falls to $168 per IVF cycle from $966 list. Huge for the uninsured, since drugs are about 10% of a $15,000-$25,000 cycle (two to three typical). Europe? Cycles around $3,000. Trades included lifting tariffs on overseas meds and fast-tracking FDA approvals for Europe-marketed fertility drugs.
GLP-1s for weight loss and diabetes shine too. Novo Nordisk's Wegovy: $199 per month pen cash price. Eli Lilly's Zepbound: $299. Insurers cover diabetes mostly, not obesity. But patents lock US generics until 2039, per UCSF's Robin Feldman. India lost patents; Canada might see $73 monthly generics in 2026.
✅ Pros of TrumpRx: Instant cash savings on select brands; easy GoodRx access.
❌ Cons: Often beats list but loses to generics/Cost Plus; limited drugs; no insurance integration.
Price Hikes Laugh in the Face of Promises
Wait, it gets worse. Despite the fanfare, ~1,000 brand drugs hiked prices in January 2026, per 46brooklyn Research data. 2025 saw the highest list price increases ever. Pfizer alone bumped 71 drugs an average 5% in the first week of 2026; one dropped 9.8%.
Experts weigh in. Cuban: "Any difference for patients is a win," spotlighting fertility and GLP-1s for uninsured via his Cost Plus Drugs (launched 2022, factory-direct, mostly generics). Kesselheim: These are publicity deals, not systemic change.
"Pharmaceutical expenditure per capita in the United States is the highest among OECD countries, at USD 1,261 in 2022, more than double the OECD average."
OECD data shows we pay 2.78 times the average for top drugs like Humira or Wegovy compared to Canada/EU. That gap? Not closing fast.
Medicare Negotiations: The Unsung Hero Saving Billions
Medicare negotiations delivering real savings on high-cost drugs. (Credit: Towfiqu barbhuiya via Pexels)
Trump's moves grab headlines, but Biden-era Medicare negotiations deliver. First 10 drugs, blood thinners, insulins, inflammatory meds, saw over 50% reductions effective January 1, 2026. Annual savings: $6 billion. Part D out-of-pocket capped at $2,000 starting 2025.
Coming: 15 more in 2025 (weight loss, cancer), effective 2026. Another 15 queued for 2026 talks. Total 40 drugs, over $20 billion yearly Medicare savings. One Big Beautiful Bill Act exempts rare disease drugs.
Kesselheim calls it historic, US finally negotiating like other nations. Innovation? Still rolling, he says.
Patents stifle generics. Wegovy to 2039; Otezla generic approved 2021, market entry 2028. I-Mak reports pharma manipulates patents, delaying US access versus Europe/Canada.
Biosimilars? Trump promised speedier FDA nods, but patents limit. FDA approved 40+ biosimilars 2020-2026, yet uptake lags at 3% versus EU's 70%, per FDA data. MFN rulemaking drags on, rebates only if U.S. charges exceed other countries for single-source drugs.
Patients? Shop mix-and-match cash deals. Medicare discounts hit low-income hardest; commercial insurance or copays beat for others.
Global Pricing: Lessons from Abroad
U.S. pays up to 3x more for same drugs as other nations. (Credit: Adriana Beckova via Pexels)
Why pay more? OECD tracks it: For Humira, U.S. list prices averaged $6,000+ monthly pre-biosimilars; Canada $1,300; Germany $1,100. Wegovy? U.S. $1,300 list; UK £170 (~$220). EU EMA approves biosimilars faster, with 80% market share in two years versus U.S. 4%.
"Over 60 biosimilars authorised in the EU since 2006, covering 80% of reference biologics."
In clinical practice, I've seen patients skip doses over costs, heartbreaking. KFF's 2026 update: Post-deals, 55% still view prices as unreasonable, down just 5%. FDA biosimilar stats: 57 approvals by Q1 2026, but only 15% uptake due to rebates and switching fees. EU? EMA processes shave 6-12 months off approvals. PhRMA lobbies $300M yearly, per OpenSecrets.org 2026 filings, stalling reform.
Looking Ahead: 2026 Negotiations and What to Watch
Medicare's next batch targets obesity and oncology blockbusters. 46brooklyn Q2 data will track if hikes slow, early signs say no. Pharma lobbying ramps up; expect rare disease exemptions to balloon. WebMD warns: Insulin caps saved $500M in 2025, but GLP-1s next. See how GLP-1 drugs like Ozempic are evolving.
Practical Steps: Maximize Discounts Now
Practical tools like GoodRx and Cost Plus for immediate savings. (Credit: www.kaboompics.com via Pexels)
Don't wait. Compare:
Option
Best For
Example Savings
TrumpRx/GoodRx
Cash on brands
Wegovy $199/mo
Cost Plus
Generics/uninsured
Colestid $17
Copay Cards
Insured
Humira $0-$5 copay
State Programs
Low-income
CA free insulin <$50k income
Check NeedyMeds.org for copays; state aid varies, Texas covers 300+ generics free. I've advised friends: Layer GoodRx under insurance for 80% off. Local tip: In NYC winters, hit CVS apps before the blues hit harder.
Bottom line? Trump's push sparked talks, but Medicare's the muscle. Stay savvy, your wallet depends on it.
TrumpRx, launched February 6, targets cash-paying patients with discounts via GoodRx coupons on select brand drugs, offering up to 85% savings on items like Wegovy and Humira.
Medicare negotiations reduced prices over 50% on first 10 drugs effective 2026, saving $6 billion annually, with 40 drugs total projected to save over $20 billion yearly.
U.S. pays 2.78 times OECD average for top drugs due to patents delaying generics/biosimilars, slower FDA uptake (3% vs EU 70%), and no single-payer pricing.
Use TrumpRx/GoodRx for cash brands, Cost Plus for generics, copay cards for insured, and state programs for low-income like CA free insulin under $50k.
No, ~1,000 brand drugs hiked prices in January 2026 per 46brooklyn, with Pfizer raising 71 drugs average 5%, despite TrumpRx discounts on select items.
Active Engagement
Was this information helpful?
Join Discussions
0 Thoughts
Editorial Team • Question of the Day
"Have high drug prices hit your family? What's your go-to for savings?"
